Navidea Biopharmaceuticals Opens Boston-area Business and Commercial Development Office
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has opened a business and commercial development office in Andover, MA, just outside of Boston. The new office will house the Company’s commercialization team handling in part the activities surrounding the anticipated launch of Lymphoseek later this year. Navidea’s corporate headquarters, with clinical, manufacturing, regulatory and administration functions, remains in Dublin, Ohio.
“We are pleased to announce this expansion into the Boston area, a major hub of the biopharmaceutical industry, which will enhance our access to industry partners, key business and technical leaders, and major academic medical centers,” said Dr. Mark Pykett, Navidea President and CEO. “This is an important commercial and business development expansion for us, complementing our established Ohio-based corporate office, as we prepare for the anticipated marketing approval in the U.S. for Lymphoseek, international activities for the product, and the growth of our radiopharmaceutical pipeline.”
The address for the Boston office is:
|Navidea Biopharmaceuticals, Inc.
|10 New England Business Center, Suite 112
|Andover, MA 01810
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the presence and status of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Sr. VP & CFO
Source: Navidea Biopharmaceuticals, Inc.
Released February 8, 2012